Establishment Labs Holdings Inc. $ESTA Holdings Decreased by Royce & Associates LP

Royce & Associates LP lowered its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 1.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 464,708 shares of the company’s stock after selling 7,608 shares during the quarter. Royce & Associates LP’s holdings in Establishment Labs were worth $29,820,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in ESTA. CenterBook Partners LP lifted its stake in shares of Establishment Labs by 123.9% in the 3rd quarter. CenterBook Partners LP now owns 9,033 shares of the company’s stock valued at $580,000 after purchasing an additional 4,999 shares during the period. State of Wyoming grew its stake in Establishment Labs by 102.1% during the third quarter. State of Wyoming now owns 2,057 shares of the company’s stock worth $132,000 after purchasing an additional 1,039 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Establishment Labs by 220.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,560 shares of the company’s stock worth $163,000 after purchasing an additional 1,760 shares in the last quarter. Sterling Capital Management LLC increased its holdings in Establishment Labs by 849.5% in the third quarter. Sterling Capital Management LLC now owns 902 shares of the company’s stock worth $58,000 after purchasing an additional 807 shares in the last quarter. Finally, State of Alaska Department of Revenue acquired a new position in Establishment Labs in the third quarter valued at approximately $80,000. 72.91% of the stock is owned by institutional investors.

Establishment Labs Stock Up 3.1%

Establishment Labs stock traded up $2.13 during midday trading on Friday, reaching $70.75. The stock had a trading volume of 367,353 shares, compared to its average volume of 513,910. The company has a fifty day moving average price of $66.04 and a two-hundred day moving average price of $72.37. Establishment Labs Holdings Inc. has a 12 month low of $53.16 and a 12 month high of $97.59. The company has a current ratio of 3.57, a quick ratio of 2.52 and a debt-to-equity ratio of 17.17. The company has a market capitalization of $2.11 billion, a P/E ratio of -55.27 and a beta of 1.03.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Friday, October 30th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.09). Establishment Labs had a negative return on equity of 196.38% and a negative net margin of 14.56%. The firm had revenue of $71.99 million during the quarter, compared to the consensus estimate of $66.81 million. During the same quarter in the previous year, the company posted ($0.38) EPS. The firm’s revenue was up 33.8% on a year-over-year basis. As a group, equities analysts expect that Establishment Labs Holdings Inc. will post -1.18 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Needham & Company LLC increased their price target on Establishment Labs from $86.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. TD Cowen lowered their price objective on shares of Establishment Labs from $117.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, October 26th. BTIG Research dropped their target price on shares of Establishment Labs from $103.00 to $93.00 and set a “buy” rating on the stock in a research report on Thursday, October 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday, September 21st. Finally, Citigroup raised shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 target price on the stock in a research note on Thursday, August 13th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $95.00.

About Establishment Labs

Establishment Labs Holdings Inc. is a medical technology company focused on breast health and aesthetics. Founded in 2004 by Juan José Chacón-Quirós, the Costa Rica-based company develops and manufactures products for breast augmentation and reconstruction. Its product portfolio includes Motiva breast implants, offered in different shapes and designs, as well as related technologies and products for plastic and reconstructive surgery. The company also develops solutions intended to support surgical procedures and patient care.